Opinion|Videos|February 10, 2025
Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems
Author(s)Debra Fromer, MD
An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-Spectrum β-lactamase-phenotype Gram-negative Enterobacterales,” including its objective, design, methodology, results, and key takeaways, and discusses how this data impacts the treatment of inpatient uncomplicated UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly describe the study “Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-spectrum β-lactamase-phenotype Gram-negative Enterobacterales.”
- What was the objective of this study?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. How does this data impact how you treat inpatient UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Sotatercept Indication for PAH
2
Proactive MG Management Hinges on Better Coverage and Guidelines
3
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
4
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
5
